Abstract
Aims: This study aims to analyze the dose and length of hypnotic and sedative drug prescriptions under a free-to-visit health insurance system. Study Design: Outpatients aged 15 years and older covered by the Taiwan National Health Insurance during 2007 (N=1,337,444) are included in this study. Methodology: The total amount of prescriptions for each patient was described according to the WHO Defined Daily Dosage (DDD) equivalent. Participants were categorized into 4 groups by dimensions of length (90 days) and dose (3 DDD per day). Patient characteristics and prescription drug use patterns were examined using a multinomial logit regression. Results: Although most prescription doses fell within the recommended ranges, the Original Research Article British Journal of Medicine & Medical Research, 4(7): 1577-1590, 2014 1578 average flunitrazepam dose was substantially higher than that recommended for both long-term and high-dose users. Our results indicate that male sex, a psychiatric illness diagnosis, and receiving care at more than one institute were positively correlated with long-term use. However, these factors were negatively correlated with high-dose user. Distinct differences between the characteristics associated with long-term and high-dose use were observed, compared with normal users. Conclusion: These findings call for clinicians and policy makers to focus their attention on potential safety and efficiency issues. The alignment of prescribing practices and guidelines is highly recommended.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.